StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
17
This year
1
Publishing Date
2024 - 01 - 16
1
2023 - 11 - 03
1
2023 - 10 - 04
1
2023 - 07 - 10
1
2022 - 11 - 03
1
2022 - 10 - 03
1
2022 - 03 - 28
1
2022 - 02 - 12
1
2021 - 12 - 21
1
2021 - 11 - 22
1
2021 - 10 - 25
1
2021 - 10 - 09
1
2021 - 10 - 01
1
2021 - 06 - 15
1
2021 - 05 - 03
1
2021 - 03 - 02
1
2021 - 01 - 12
1
Sector
Health technology
17
Tags
Aaviate
1
Altitude
2
Application
2
Approval
1
Arcatus
1
Arvn001
1
Arvn004
1
Australia
1
Axitinib
4
Biocanada
1
China
1
Clinical-trials-phase-i
1
Clinical-trials-phase-ii
3
Clinical-trials-phase-iii
1
Cls-ax
4
Diabetes
2
Diabetic
4
Dmd
3
Drug
2
Ema
2
Enroll
1
Expansion
1
Fda
1
Fda approval
1
Injection
4
Liver
3
Macular
6
N/a
8
New drug
1
One
1
Phase 1
4
Phase 2
3
Phase 3
3
Positive
9
Product-news
1
Regulatory
1
Research
1
Resubmission
1
Results
2
Retina
2
Rgx-314
5
Submission
1
Treatment
17
Trial
11
Trials
1
Xipere
4
Year
1
Entities
3m company
21
Abbott laboratories
62
Abbvie inc.
121
Accuray incorporated
21
Adamis pharmaceuticals corporation
19
Adial pharmaceuticals, inc
22
Alnylam pharmaceuticals, inc.
38
Amgen inc.
47
Arcutis biotherapeutics, inc.
25
Arrowhead pharmaceuticals, inc.
21
Astellas pharma inc
52
Astrazeneca plc
52
Bausch health companies inc.
36
Biogen inc.
42
Biohaven pharmaceutical holding company ltd.
19
Bioxcel therapeutics, inc.
20
Boston scientific corporation
21
Brainsway ltd.
41
Bridgebio pharma, inc.
20
Bristol-myers squibb company
94
Cns pharmaceuticals, inc.
26
Coherus biosciences, inc.
28
Compass pathways plc
20
Ecolab inc.
47
Eli lilly and company
180
Fortress biotech, inc.
27
Gilead sciences, inc.
50
Glaxosmithkline plc
103
Hoth therapeutics, inc.
24
Incyte corporation
77
Intellia therapeutics, inc.
32
Jazz pharmaceuticals plc
20
Johnson & johnson
211
Karyopharm therapeutics inc.
33
Koninklijke philips n.v.
21
Medicinova, inc.
24
Medtronic plc
46
Merck & company, inc.
66
Moleculin biotech, inc.
28
Novartis ag
145
Novo nordisk a/s
37
Nrx pharmaceuticals inc
20
Orange
87
Perrigo company
23
Pfizer, inc.
75
Reata pharmaceuticals, inc.
28
Regeneron pharmaceuticals, inc.
57
Regenxbio inc.
25
Sanofi
298
Sorrento therapeutics, inc.
37
Takeda pharmaceutical company limited
55
Teleflex incorporated
21
Teva pharmaceutical industries ltd
79
Tg therapeutics, inc.
24
Tonix pharmaceuticals holding corp.
32
Ultragenyx pharmaceutical inc.
25
Verrica pharmaceuticals inc.
23
Vertex pharmaceuticals incorporated
27
Viatris inc.
46
Xylem inc.
35
Symbols
BHC
3
CLSD
17
RGNX
7
SRPT
1
Exchanges
Nasdaq
17
Nyse
3
Crawled Date
2024 - 01 - 16
1
2023 - 11 - 03
1
2023 - 10 - 04
1
2023 - 07 - 10
1
2022 - 11 - 03
1
2022 - 10 - 03
1
2022 - 03 - 28
1
2022 - 02 - 12
1
2021 - 12 - 21
1
2021 - 11 - 22
1
2021 - 10 - 25
1
2021 - 10 - 09
1
2021 - 10 - 02
1
2021 - 06 - 15
1
2021 - 05 - 03
1
2021 - 03 - 02
1
2021 - 01 - 12
1
Crawled Time
00:20
1
11:00
2
12:00
3
13:00
4
13:01
1
16:20
1
19:00
2
20:00
1
20:20
1
23:00
1
Source
www.biospace.com
9
www.globenewswire.com
4
www.prnewswire.com
4
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
treatment
entities :
Clearside biomedical, inc.
save search
REGENXBIO Announces Positive Interim Data from Phase II AAVIATE® Trial of ABBV-RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery
Published:
2024-01-16
(Crawled : 20:00)
- prnewswire.com
SRPT
|
$117.12
0.14%
0.09%
570K
|
Health Technology
|
1.5%
|
O:
-0.49%
H:
3.17%
C:
1.94%
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
4.13%
|
O:
-0.13%
H:
0.0%
C:
-7.15%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-4.86%
|
O:
0.0%
H:
0.0%
C:
-6.94%
rgx-314
aaviate
positive
treatment
trial
REGENXBIO Presents Positive One Year Data from Phase II ALTITUDE® Trial of ABBV-RGX-314 for Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2023-11-03
(Crawled : 23:00)
- prnewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
Email alert
Add to watchlist
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
Email alert
Add to watchlist
rgx-314
altitude
year
one
positive
treatment
trial
diabetic
Clearside Biomedical Announces Advancement of XIPERE® in Asia-Pacific for Suprachoroidal Treatment of Uveitic Macular Edema as Partner Arctic Vision Completes Enrollment in Phase 3 Clinical Trial in China
Published:
2023-10-04
(Crawled : 13:00)
- globenewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
61.33%
|
O:
-3.44%
H:
6.1%
C:
3.66%
xipere
macular
treatment
trial
china
Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema
Published:
2023-07-10
(Crawled : 11:00)
- globenewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
28.04%
|
O:
0.0%
H:
3.71%
C:
-0.93%
arcatus
drug
australia
macular
treatment
application
REGENXBIO Presents Positive Interim Data from and the Expansion of Phase II ALTITUDE® Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2022-11-03
(Crawled : 12:00)
- biospace.com/
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
-34.41%
|
O:
-3.01%
H:
0.77%
C:
-10.46%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
1.48%
|
O:
0.74%
H:
11.76%
C:
7.35%
rgx-314
altitude
treatment
expansion
trial
positive
diabetic
REGENXBIO Announces Additional Positive Interim Data from Trials of RGX-314 for the Treatment of Wet AMD
Published:
2022-10-03
(Crawled : 13:00)
- biospace.com/
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
-39.84%
|
O:
2.16%
H:
0.3%
C:
-10.48%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
21.24%
|
O:
0.88%
H:
5.26%
C:
5.26%
rgx-314
treatment
trials
positive
Bausch + Lomb and Clearside Biomedical Announce the U.S. Commercial Launch of XIPERE® (Triamcinolone Acetonide Injectable Suspension) For Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published:
2022-03-28
(Crawled : 19:00)
- biospace.com/
BHC
|
$8.53
0.95%
0.0%
4M
|
Health Technology
|
-62.62%
|
O:
-0.35%
H:
0.09%
C:
-0.7%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-41.95%
|
O:
2.97%
H:
2.47%
C:
-3.7%
xipere
treatment
macular
REGENXBIO Presents Positive Interim Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery
Published:
2022-02-12
(Crawled : 20:20)
- prnewswire.com
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
Email alert
Add to watchlist
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
Email alert
Add to watchlist
rgx-314
treatment
liver
trial
positive
diabetic
diabetes
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-12-21
(Crawled : 13:00)
- biospace.com/
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-52.76%
|
O:
-1.03%
H:
4.18%
C:
0.7%
treatment
axitinib
trial
cls-ax
phase 1
positive
results
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME)
Published:
2021-11-22
(Crawled : 19:00)
- biospace.com/
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-68.65%
|
O:
0.0%
H:
0.69%
C:
-10.98%
arvn001
treatment
ema
macular
arvn004
Bausch + Lomb and Clearside Biomedical Announce FDA Approval of XIPERE™ (triamcinolone acetonide injectable suspension) for Suprachoroidal Use for the Treatment of Macular Edema Associated with Uveitis
Published:
2021-10-25
(Crawled : 11:00)
- biospace.com/
BHC
|
$8.53
0.95%
0.0%
4M
|
Health Technology
|
-70.25%
|
O:
0.28%
H:
1.95%
C:
0.9%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-74.86%
|
O:
3.49%
H:
8.51%
C:
-0.89%
treatment
fda
ema
fda approval
approval
macular
xipere
injection
REGENXBIO Presents Positive Initial Data from Phase II ALTITUDE™ Trial of RGX-314 for the Treatment of Diabetic Retinopathy Using Suprachoroidal Delivery at American Society of Retina Specialists Annual Meeting
Published:
2021-10-09
(Crawled : 16:20)
- prnewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
Email alert
Add to watchlist
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
Email alert
Add to watchlist
treatment
positive
retina
liver
trial
diabetic
diabetes
REGENXBIO Presents Positive Initial Data from Phase II AAVIATE® Trial of RGX-314 for the Treatment of Wet AMD Using Suprachoroidal Delivery and Provides Trial Update at Retina Society 54th Annual Scientific Meeting
Published:
2021-10-01
(Crawled : 00:20)
- biospace.com/
RGNX
|
$15.9
1.66%
1.54%
360K
|
Health Technology
|
-62.07%
|
O:
0.5%
H:
0.0%
C:
0.0%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-77.17%
|
O:
-1.5%
H:
0.0%
C:
0.0%
treatment
positive
retina
liver
trial
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-06-15
(Crawled : 12:00)
- biospace.com/
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-54.64%
|
O:
32.42%
H:
20.02%
C:
4.03%
treatment
phase 1
positive
results
trial
phase 3
phase 2
axitinib
cls-ax
dmd
injection
Clearside Biomedical Announces Resubmission of New Drug Application for XIPERE™ for Treatment of Macular Edema Associated with Uveitis
Published:
2021-05-03
(Crawled : 12:00)
- biospace.com/
BHC
|
$8.53
0.95%
0.0%
4M
|
Health Technology
|
-73.48%
|
O:
0.09%
H:
0.68%
C:
-2.42%
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-55.37%
|
O:
1.63%
H:
1.28%
C:
-4.49%
new drug
treatment
drug
macular
submission
xipere
application
resubmission
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-03-02
(Crawled : 13:01)
- globenewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-60.29%
|
O:
3.48%
H:
0.28%
C:
-4.48%
treatment
phase 1
trial
phase 3
phase 2
axitinib
cls-ax
dmd
injection
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published:
2021-01-12
(Crawled : 13:00)
- globenewswire.com
CLSD
|
News
P
|
$1.37
-2.84%
-3.68%
230K
|
Health Technology
|
-62.67%
|
O:
0.54%
H:
1.36%
C:
-2.44%
trial
phase 3
phase 1
phase 2
treatment
axitinib
cls-ax
dmd
injection
enroll
Gainers vs Losers
78%
22%
Top 10 Gainers
MTTR
|
News
4
|
$4.6
164.37%
62.17%
26M
|
AGBA
|
$2.97
137.6%
57.48%
66M
|
Finance
EDBL
|
News
|
$6.59
75.27%
41.8%
2M
|
MTC
|
$2.24
43.59%
30.67%
6M
|
Technology Services
OPRT
|
News
|
$3.15
40.0%
29.13%
12M
|
Finance
SHIM
|
$3.045
35.33%
26.23%
870K
|
HKIT
|
$1.33
30.39%
24.16%
390K
|
Technology Services
ABVC
|
$1.35
29.81%
23.53%
7.1M
|
Wholesale Trade
OST
|
$0.5
25.0%
21.88%
280K
|
POET
|
$1.59
27.2%
21.38%
4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.